NCT02007850

Brief Summary

Quadriceps muscle strength is an important determinant of quality of recovery in elderly patients after total knee arthroplasty. We try to compare the quadriceps muscle strength change between 0.2 % ropivacaine continuous fixed femoral infusion and patient controlled femoral analgesia group.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 28, 2013

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 11, 2013

Completed
2 months until next milestone

Study Start

First participant enrolled

February 1, 2014

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2015

Completed
Last Updated

July 30, 2014

Status Verified

July 1, 2014

Enrollment Period

1 year

First QC Date

October 28, 2013

Last Update Submit

July 29, 2014

Conditions

Keywords

continuous femoral nerve blockknee arthroplastyquadriceps muscle strength

Outcome Measures

Primary Outcomes (1)

  • Change of quadriceps muscle strength

    maximum voluntary isometric contraction of quadriceps femoris with hand held manometry

    Baseline, Postoperative 2nd day

Secondary Outcomes (4)

  • sensory changes in femoral nerve distribution

    postoperative 2 day

  • pain scores

    postoperative 1 day

  • pain scores

    postoperative 2 day

  • intravenous fentanyl consumption

    postoperative 2 day

Study Arms (2)

ropivacaine continuous mode

PLACEBO COMPARATOR

0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl

Drug: ropivacaine

ropivacaine patient controlled mode

ACTIVE COMPARATOR

0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl

Drug: ropivacaine

Interventions

Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery

Also known as: femoral nerve block
ropivacaine continuous moderopivacaine patient controlled mode

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \> 21, or \< 80 years old- men and women
  • primary, unilateral total knee replacement surgery
  • spinal anesthesia

You may not qualify if:

  • general anesthesia
  • secondary knee replacement surgery
  • patient refusal for continuous femoral nerve analgesia technique
  • abnormal coagulation profile, e.g. Prothrombin time international normalized ratio \> 1.5, activated partial thrombin time \> 50 sec
  • within 5 days after termination oral antiplatelet agent
  • Body mass index\>45
  • impaired renal function
  • infection near femoral area
  • previous injury near femoral area
  • neurologic dysfunction in lower limb
  • previous adverse drug reaction for local anesthetics
  • American society of anesthesiologists (ASA) class III, iV or V

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Sungnam, Gyungido, 463-707, South Korea

RECRUITING

MeSH Terms

Conditions

Muscle Weakness

Interventions

Ropivacaine

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Hae Wone Chang, M.D.

    Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Hae Wone Chang, M.D

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Associate Professor

Study Record Dates

First Submitted

October 28, 2013

First Posted

December 11, 2013

Study Start

February 1, 2014

Primary Completion

February 1, 2015

Study Completion

July 1, 2015

Last Updated

July 30, 2014

Record last verified: 2014-07

Locations